Background: Prostate cancer (PCa) is one of the most common types of cancer among men.
Mutations and accumulation of chromosomal deviations are correlated with the development …

Castration-resistant prostate cancer (CRPC) is the final stage of prostate cancer (PCa). As
the main androgen in males, testosterone, and its androgen receptor (AR) play an important …

Prostate cancer progression and treatment relapse is associated with changes in the
androgen receptor axis, and analysis of alternations of androgen receptor signaling is …

The molecular cause of prostate cancer (PCa) is still unclear; however, its progression
involves androgen, PI3K/Akt, and PTEN signaling, as cycle and apoptotic pathways …

Current therapies for prostate cancer include antiandrogens, inhibitory ligands of the
androgen receptor, which repress androgen-stimulated growth. These include the selective …

To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both
the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study …

Acquired or inherited genetic alterations either alone or in combination with epigenetic
alterations are associated with prostate carcinogenesis and its progression toward advance …

Genetic sex in mammals is determined by the sex chromosomal composition of the zygote.
The X and Y chromosomes are responsible for numerous factors that must work in close …

Aim Androgen receptor splice variants (AR-Vs) produced by alternative splicing of the AR
play an important role in the treatment resistance and progression of prostate cancer (PCa) …

Adenoid cystic carcinoma is an unusual histological variant of prostatic carcinoma. Because
of its rarity, the natural history of this tumor is not known. Here we report this rare entity in a …